Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167968 | 0.85 | MEN1 (0.43) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL615375 | 0.83 | MAPT (0.35) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL1167633 | 0.82 | MEN1 (0.35) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL617789 | 0.79 | PTGS2 (0.34) | — | |
| SCHEMBL618905 | 0.78 | BRD4 (0.30) | — | |
| SCHEMBL617270 | 0.69 | KMT2A (0.62) | MEN1LMNAGAAMAPTKMT2A | |
| SCHEMBL1168014 | 0.65 | NPC1 (0.32) | MEN1MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL617799 | 0.65 | PDE4A (0.31) | MAPT | |
| SCHEMBL1168498 | 0.63 | KDM4E (0.32) | MEN1MAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL5269354 | 0.63 | HSP90AA1 (0.48) | MEN1LMNAGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-8058297-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1966172-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | MEN1 4135/4885LMNA 4831/4885GAA 3287/4885 |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | MEN1 1571/4885LMNA 2274/4885GAA 597/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | MEN1 1571/4885LMNA 2274/4885GAA 597/4885 |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | MEN1 1571/4885LMNA 2274/4885GAA 597/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | MEN1 1571/4885LMNA 2274/4885GAA 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.